Canary Bio Participates in 2022 JP Morgan Healthcare Conference... "Pipeline Introduction"
[Asia Economy Reporter Hyunseok Yoo] Canaria Bio announced on the 7th that it will participate in the 2022 JP Morgan Healthcare Conference, which is being held virtually.
Nahanik, CEO of Canaria Bio, stated, "At this event, we plan to introduce the company's major pipelines such as ovarian cancer, pancreatic cancer, and metastatic breast cancer, and seek strategic partnerships with global pharmaceutical companies."
Canaria Bio, in collaboration with its affiliates, is promoting a new immuno-oncology drug development business with the ovarian cancer treatment 'Oregobomab' as its core pipeline. Oregobomab, one of the major pipelines, showed an increase of 30 months in progression-free survival compared to existing treatments through global Phase 2 clinical trial results.
Hot Picks Today
Even with High Oil Price Relief Payment, Additional 300,000 Won Per Person to Be Provided... Applications Open from the 18th in This Region
- "Invested 95% in Hynix and Reached 10 Billion Won"... Japanese Investor's Proof Post Goes Viral
- "Why Is the Korean Stock Market Surging?"... Even Italy Is Astonished by the KOSPI Rally
- "You Don't Need to Go to the Gym": The Best Exercises for Lowering Hypertension
- "That Thing Wakes Up Every Night" ... Suspicious Object Covers Rural Village
Currently, global Phase 3 clinical trials are underway at 120 clinical sites in 11 countries. In addition, another pipeline, the pancreatic cancer treatment AR20.5, is preparing for Phase 2 clinical trials.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
